An end-to-end approach to managing wearable devices through clinical development
Effective monitoring of clinical trial participants is critical for patient protection and study integrity. However, as the complexity of modern clinical trials grows, on-site monitoring has proven to be expensive and inefficient. As a result, wearable devices have been increasingly used to capture and transmit patient data remotely. These practices increase clinical trial efficiency, while reducing some of the barriers to clinical trial participation, enabling patients to access care from their homes. Other benefits of adopting wearables include:
- Increased patient engagement
- New clinical endpoints
- Robust patient screening
- Real-time compliance monitoring
- More flexible adaptive trials
- Improved data quality
Despite these benefits, wearable devices may present drug developers with challenges when they are integrated in trial design, execution and reporting. As such, it is important to have an end-to-end approach to adopting wearable devices – from device selection to endpoint generation and operational management.
Our team has experience leveraging wearable devices in clinical trials, and can help you develop a framework for device selection and digital endpoints.
Device selection
With new devices entering the market everyday, proper device selection is critical for operational excellence and patient engagement. Study teams and patients must be properly trained so that they are comfortable using study devices.
Other key considerations during device selection include:
- Assessment of study objectives (type of data, blinded/unblinded, therapeutic area, etc.)
- Patient centricity (compliance, patient burden assessment, user friendliness, engagement, etc.)
- Device characteristics (validation, fit for purpose, connectivity, etc.)
- Big data (storage, EDC, etc.)
- Regulatory considerations
- Privacy and security
Advancing digital endpoints
As digital health technologies become increasingly used in clinical trial protocols, early adopters willing to invest in these technologies may win market share, while those without sufficient investments may find themselves at a disadvantage.
Discover a framework for integrating digital health effectively and efficiently in this whitepaper.
Digital endpoints
We are committed to advancing methodology and innovation to support novel endpoints. Our clinical endpoints framework is based on proven PRO methodologies to ensure that data collected using wearables meet evidentiary requirements for regulatory submission.
Potential endpoints to be collected using wearables may include:
|
|
Webinar
Digital Endpoint Strategy and Validation
- Present a strategy to identify devices that are "fit for purpose"
- Outline a framework for Digital Endpoint selection and validation to ensure the outcome measurement is robust, reliable, and interpretable
- Address the key considerations that arise when using digital technology to support endpoint generation in clinical studies such as Device Selection, Endpoint Reliability and Sensitivity, Meaningful Change Thresholds, and Analysis Strategy and Interpretation
Decentralised & hybrid trial insights
ICON's Decentralised & Hybrid clinical trial experts provide analysis including whitepapers, blogs and contributions to media and industry conversations relating to all aspects of decentrilisation in clinical trials.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
- Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel